3 Major Health-Care Deals You Need to Know About

Forest Laboratories, Inc.'s (NYSE: FRX) purchase of Aptalis is just the latest in a plethora of major health-care deals.

Feb 10, 2014 at 11:11PM

The year is only a handful of weeks old, and already there has been a raft of takeover activity among major pharmaceutical stocks!

Most recent was the completion of a $2.9 billion purchase of Aptalis, a company that manufactures treatments for cystic fibrosis and gastrointestinal problems, by Forest Laboratories (NYSE:FRX).

The move is said to generate an additional $700 million in revenue per year for Forest Laboratories, and, crucially, the market seems to have welcomed it. Shares of Forest Laboratories are up more than 17% since the deal was first announced despite a weak wider market. Year to date, Forest Laboratories has beaten the S&P 500 by just under 18% -- highlighting how popular the acquisition is on the Street.

The move forms part of a new strategy under Brenton Saunders, CEO, as he seeks to increase medium- to long-term growth prospects. As well as this major acquisition, Forest Laboratories is set to cut costs by around $500 million and commence a large-scale share buyback of $400 million in 2014, with the company also lining up further acquisitions in addition to the Aptalis deal and the purchase of U.S. marketing rights to Merck's schizophrenia drug, Saphris.

However, the purchase of Aptalis isn't the only major deal of 2014. Just last week, Bristol-Myers Squibb (NYSE:BMY) and AstraZeneca (NYSE:AZN) confirmed the latter's purchase of the former's stake in the diabetes alliance joint venture for an initial sum of $2.7 billion.

The deal seems to be a convenient move for both companies, as Bristol-Myers Squibb attempts to restructure away from being a drug manufacturer for the masses and instead seeks to focus on specialist, niche-product offerings.

Meanwhile, AstraZeneca spent much of 2013 on an acquisition spree as it seeks to overcome a patent cliff (resulting from generic competition) that has caused a severe demise in total sales and net profit. However, with diabetes remaining a high-growth area (where the number of sufferers is set to increase from more than 300 million to more than 500 million in the next 20 years), it could prove to be a good move for AstraZeneca.

In addition to those deals, the biggest of them all has seen Johnson & Johnson (NYSE:JNJ) sell its blood-testing unit to private-equity outfit Carlyle Group for just over $4 billion. The move is part of a shift from what Johnson & Johnson deems to be lower-growth divisions, as it seeks to reinvigorate a top line that has struggled to post much growth in the last handful of years.

So, while interest rates remain low and health-care companies continue to benefit from having relatively low debt levels and the financial flexibility that such a situation brings, dealmaking could continue to feature during the rest of 2014.

Certainly, there are a number of major pharmaceutical companies that are struggling to cope with the effects of generic competition and, as a result, are seeking to buy top- and bottom-line growth. As such, the pace of dealmaking year-to-date may not abate just yet.

The Motley Fool's top stock for 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Peter Stephens owns shares of AstraZeneca. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers